Table 1.
Mean score for psychological resilience (CD-RISC25) at 1 year post diagnosis, and mean change in psychological resilience score between 1 year post diagnosis and diagnosis (delta-CD-RISC25) according to demographic and clinicopathological characteristics.
| Variables | n | % | CD-RISC25 at 1 Year Post Diagnosis |
delta-CD-RISC25 (Score at 1 Year Post Diagnosis Minus Score at Diagnosis) |
|||
|---|---|---|---|---|---|---|---|
| Mean (SD) | p-Value A | Mean (SD) | p-Value A | ||||
| Follow-up cohort | - | 418 | 68.9 (14.0) | - | −1.7 (10.5) | - | |
| Study site | Halmstad | 135 | 32 | 68.5 (13.7) | 0.587 | −1.6 (10.6) | 0.961 |
| Helsingborg | 20 | 5 | 71.7 (19.2) | −2.4 (9.0) | |||
| Karlskrona | 120 | 29 | 69.8 (13.6) | −1.3 (10.6) | |||
| Växjö | 143 | 34 | 68.1 (13.8) | −1.9 (10.6) | |||
| Age (years) | Mean (SD): 62 (11) | - | - | - | - | - | - |
| ≤64 (median) | 214 | 51 | 69.9 (12.9) | 0.134 | −1.7 (10.0) | 0.954 | |
| >64 (median) | 204 | 49 | 67.8 (15.0) | −1.6 (11.0) | |||
| Menstrual status | Premenopausal | 74 | 19 | 72.3 (13.7) | 0.024 | −2.1 (11.2) | 0.699 |
| Postmenopausal | 325 | 81 | 68.2 (14.1) | −1.5 (10.4) | |||
| Unknown | 19 | ||||||
| Mode of detection | Screening | 269 | 65 | 69.0 (13.5) | 0.764 | −0.8 (10.2) | 0.022 |
| Symptomatic | 148 | 35 | 68.6 (14.9) | −3.3 (10.9) | |||
| Unknown | 1 | ||||||
| Stage | 0 | 24 | 6 | 69.9 (13.8) | 0.114 | 0.8 (7.0) | 0.691 |
| I | 272 | 65 | 68.0 (14.3) | −1.9 (10.7) | |||
| II | 117 | 28 | 70.4 (13.0) | −1.7 (10.7) | |||
| III | 3 | 1 | 83.7 (18.3) | 0.3 (2.1) | |||
| Unknown | 2 | ||||||
| Type of breast surgery | Breast-conserving | 304 | 73 | 68.3 (14.0) | 0.136 | −1.7 (10.7) | 0.949 |
| Mastectomy | 114 | 27 | 70.5 (13.9) | −1.6 (10.0) | |||
| Unknown | 0 | ||||||
| Immediate breast reconstruction | Yes | 25 | 7 | 67.6 (12.7) | 0.540 | −1.9 (7.9) | 0.776 |
| No | 333 | 93 | 69.3 (13.9) | −1.1 (10.3) | |||
| Unknown | 60 | - | - | - | |||
| Type of axillary surgery | Sentinel node | 323 | 79 | 68.3 (14.0) | 0.200 | −1.9 (10.9) | 0.690 |
| Axillary dissection | 35 | 9 | 69.5 (13.6) | −1.4 (10.9) | |||
| Sentinel node + axillary dissection | 52 | 13 | 72.0 (13.9) | −0.76 (7.7) | |||
| Unknown | 8 | - | - | ||||
| Neoadjuvant chemotherapy | Yes | 20 | 5 | 69.7 (12.0) | 0.801 | −3.2 (11.2) | 0.505 |
| No | 398 | 95 | 68.8 (14.1) | −1.6 (10.5) | |||
| Unknown | 0 | ||||||
| Adjuvant chemotherapy | Yes | 151 | 36 | 69.6 (14.0) | 0.506 | −2.2 (9.7) | 0.307 |
| No | 267 | 64 | 68.6 (14.1) | −1.1 (10.5) | |||
| Unknown | 0 | ||||||
| Adjuvant endocrine therapy | Yes | 271 | 65 | 69.1 (14.0) | 0.693 | −1.2 (10.6) | 0.186 |
| No | 147 | 35 | 68.5 (14.2) | −2.6 (10.3) | |||
| Unknown | 0 | ||||||
| Adjuvant bisphosphonate therapy | Yes | 57 | 14 | 71.6 (11.7) | 0.074 | −2.1 (8.4) | 0.736 |
| No | 361 | 86 | 68.5 (14.8) | −1.6 (10.8) | |||
| Unknown | 0 | ||||||
| Adjuvant antibody therapy B | Yes | 45 | 11 | 67.6 (12.4) | 0.517 | −4.2 (11.1) | 0.093 |
| No | 373 | 89 | 69.0 (14.2) | −1.4 (10.4) | |||
| Unknown | 0 | ||||||
| Adjuvant radiotherapy | Yes | 334 | 80 | 68.9 (13.7) | 0.946 | −1.6 (10.5) | 0.764 |
| No | 84 | 20 | 68.8 (15.0) | −2.0 (10.4) | |||
| Unknown | 0 | - | - | - | |||
Notes: A Independent-samples t-test for comparison of means in two groups, one-way analysis of variance for comparison of three or more group means. B HER2-targeted therapy. Abbreviations: CD-RISC25, Connor-Davidson Resilience Scale 25; SD, standard deviation.